Skip to: Content
Skip to: Site Navigation
Skip to: Search

November 22, 2008 11:39:03 CST



Vets Used to Test Drugs Linked to Suicide

Posted Jun 17, 08 2:33 PM CDT in US Science & Health 

(Newser) – Combat veterans suffering post-traumatic stress disorder were recruited for clinical trials of drugs linked to suicide and mental disorders, ABC reports. In a trial involving the smoking-cessation drug Chantix, the VA did not warn patients of the drug's serious potential side effects until 3 months after the FDA and the drug's maker had issued warnings.

The VA has defended its decision to keep the study going, but medical ethicists slammed the use of already-troubled vets to test the drugs. "They never told me that I was going to be suicidal, that I would cease sleeping," said one Iraq vet who suffered a mental breakdown during the Chantix study. "They never told me anything except this will help me quit smoking."

Source ABC News

0 comments | Print E-mail | Digg Seed this on Newsvine Add this link to Del.icio.us StumbleUpon
A US. Army sergeant demonstrates a PTSD treatment in this file photo.   (AP Photo/Ted S. Warren)
US military veterans suffering post-traumatic stress disorder have been recruited for clinical trials of drugs linked to mental disorders, including the anti-smoking drug Chantix.   ((c) justj0000lie)
Combat veterans undergo therapy for PTSD in this file photo.   (KRT Photos)
« Prev« Prev | Next »Next » Slideshow
Our editors also recommend:

Threads (
1
 of 8)



Loading...

Premium Articles from HighBeam

Find more articles like this

Today's Most Popular

Loading...

Other Science & Health Stories


What is Newser?

2008 Codie Finalist

Face it: there's too much news. At Newser a team of editors and writers culls the most important stories from hundreds of U.S. and international sources and reduces them to a headline, picture, and two paragraphs. It's the Newser guarantee: we can take any report or column or video and pack what you need to know into 120 words or less. Newser's short-form aggregation, visual format, and unique information tools help you get more of the kind of news you want, in a quicker and more entertaining way. And we do it 24/7—you can come back morning, noon, night (and in between) for something new that matters. Read less, know more.

Learn more »